Moving from a GLP-1 agonist like semaglutide to a dual agonist like Tirzepatide can be effective, as the latter has shown greater average efficacy in studies
They can assess your medical history, BMI, weight loss goals, and any potential risk factors
Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinsons disease
The appetite suppression means less mental energy spent thinking about, resisting, or planning around food
Semaglutide also works by slowing down movement of food through the stomach and curbing appetite, thereby causing weight loss
Z79.4 is only added for Type 2 (E11), E08, E09, and E13 patients who use insulin